01—Abstract
Summary
Summary of the 8-K filed March 12, 2025. Cited figures are marked; the original filing is the authoritative source.
Natera, Inc. filed a Form 8-K dated March 12, 2025 under Item 5.02 to report a board change.
Effective March 6, 2025, the Board increased its size from ten to eleven members and appointed Dr. Monica Bertagnolli as a director. The Board determined she is independent under the Securities Act of 1933 and Nasdaq listing standards, and appointed her to the Nominating, Corporate Governance and Compliance Committee. She will serve as a Class III director with an initial term expiring at the 2027 annual meeting of stockholders.
Dr. Bertagnolli previously served on the Board from November 2020 until she resigned in August 2022 to become Director of the National Cancer Institute. Her compensation will be consistent with the Company's other non-employee directors, under the Amended Compensation Program for Non-Employee Directors. Her initial equity award vests in equal one-third installments on June 12, 2025, 2026, and 2027.
The Company also entered into an indemnification agreement with her. The filing states there is no arrangement or understanding under which she was elected, and no family relationships or Item 404(a) related-party interests.
For investors, this is a governance update rather than a financial disclosure. The filing contains no financial results, and its exhibits are compensation plans, an equity incentive plan, and a form of indemnification agreement incorporated by reference to earlier SEC filings.
02—Key points
Key Highlights
- Board expanded from ten to eleven members, effective March 6, 2025, with Dr. Monica Bertagnolli appointed as a new director.
- Dr. Bertagnolli was designated independent under the Securities Act of 1933 and Nasdaq listing standards.
- She joined the Nominating, Corporate Governance and Compliance Committee and serves as a Class III director with a term expiring at the 2027 annual meeting.
- Dr. Bertagnolli previously served on the Board from November 2020 to August 2022, when she resigned to become Director of the National Cancer Institute.
- Her initial equity award vests one-third each on June 12, 2025, 2026, and 2027, consistent with other non-employee directors' compensation.
- The Company entered into an indemnification agreement with her covering claims related to her Board service.
- The filing contains no financial results; exhibits consist of director compensation, equity plan, and indemnification documents incorporated by reference.
03—Questions
Frequently Asked Questions
Why did Natera add a board member?
The Board, on the recommendation of its Nominating, Corporate Governance and Compliance Committee, increased its size from ten to eleven members and appointed Dr. Monica Bertagnolli. The filing does not state further reasons.
Is Dr. Bertagnolli independent?
Yes. The Board determined she qualifies as an independent director under the Securities Act of 1933, as amended, and the Nasdaq listing standards.
What compensation will the new director receive?
She will receive cash and equity compensation consistent with the Company's other non-employee directors, as described in the Amended Compensation Program for Non-Employee Directors. Her initial equity award vests one-third each on June 12, 2025, 2026, and 2027.
Does Dr. Bertagnolli have a prior relationship with the Company?
Yes. She previously served on the Board from November 2020 until her resignation in August 2022, when she was appointed Director of the National Cancer Institute.
Does this filing report financial results?
No. The filing is limited to a board appointment under Item 5.02 and lists compensation and indemnification exhibits incorporated by reference from earlier SEC filings.
04—Continue